Drug Trial Radar · NCT04412863
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jul 3, 2020
Primary completion
Mar 25, 2024
Study completion Mar 25, 2024
Sponsor
- Lead sponsor
- Vir Biotechnology, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Alnylam Pharmaceuticals
- First posted
- Jun 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
Conditions
- Chronic Hepatitis B
Interventions
VIR-2218Drug
VIR-2218 given by subcutaneous injection
pegylated interferon-alfa 2aDrug
pegylated interferon-alfa 2a given by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Adverse Events as Assessed by CTCAE v5.0Time frame: Up to 148 Weeks
- Number of Subjects With Abnormalities in Vital Signs, Electrocardiogram (ECG), and Clinically Significant Laboratory FindingsTime frame: Up to 148 Weeks
Locations
22 sites in 6 countries. Site status is shown where the registry gives one.
Investigative Site
Birtinya, Queensland, Australia
Investigative Site
Fitzroy, Victoria, Australia
Investigative site
Hong Kong, Hong Kong
Investigative Site
Batu Caves, Malaysia
Investigative Site
Kajang, Malaysia
Investigative Site
Kuala Lumpur, Malaysia
Investigative Site
Kuantan, Malaysia
Investigative Site
Auckland, New Zealand
Investigative Site
Auckland, New Zealand
Investigative Site
Busan, South Korea
Investigative Site
Chuncheon, South Korea
Investigative Site
Daegu, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Seoul, South Korea
Investigative Site
Yangsan, South Korea
Investigative Site
Bangkok, Thailand
Investigative Site
Bangkok, Thailand
Investigative Site
Bangkok, Thailand
Investigative Site
Chiang Mai, Thailand
Investigative Site
Hat Yai, Thailand
Investigative Site
Khlong Luang, Thailand
Investigative Site
Khon Kaen, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.